Anavex Life Sciences (AVXL) Change in Accured Expenses (2010 - 2025)
Anavex Life Sciences (AVXL) reported Change in Accured Expenses of -$965000.0 for Q4 2025, down 133.31% on a YoY basis from $2.9 million in Q4 2024, and down 2508.11% sequentially from -$37000.0 in Q3 2025.
Anavex Life Sciences (AVXL) Change in Accured Expenses (2010 - 2025) Analysis & Trends
Anavex Life Sciences (AVXL) has 16 years of Change in Accured Expenses data on file, last reported at -$965000.0 in Q4 2025.
- For the quarter ending Q4 2025, Change in Accured Expenses fell 133.31% year-over-year to -$965000.0; the trailing twelve-month figure through Dec 2025 stood at -$4.8 million (down 1177.35% YoY), and the FY2025 full-year result was -$943000.0, up 61.67% from the prior year.
- Change in Accured Expenses fell to -$965000.0 in Q4 2025, from -$37000.0 in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $2.9 million in Q4 2024 to a low of -$5.6 million in Q2 2025.
- A 5-year average of -$44497.4 and a median of -$23000.0 in 2023 frame the typical range for Change in Accured Expenses.
- Peak annual rise in Change in Accured Expenses reached 32288.89% in 2024, while the deepest fall reached 977.73% in 2024.
- Tracing AVXL's Change in Accured Expenses over 5 years: stood at -$164734.0 in 2021, then surged by 766.53% to $1.1 million in 2022, then plunged by 100.82% to -$9000.0 in 2023, then soared by 32288.89% to $2.9 million in 2024, then sank by 133.31% to -$965000.0 in 2025.
- Business Quant data shows AVXL's Change in Accured Expenses at -$965000.0 in Q4 2025, -$37000.0 in Q3 2025, and -$5.6 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 1.13 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 931,000.00 |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -16.82 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 23.10 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 107.70 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -16.74 Mn |
| 10 | Anavex Life Sciences | 223.91 Mn | 92.16 Mn | - | -965,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -965,000.00 |
| Dec 31, 2025 | -965,000.00 |
| Sep 30, 2025 | -37,000.00 |
| Sep 30, 2025 | -37,000.00 |
| Jun 30, 2025 | -5.63 Mn |
| Jun 30, 2025 | -5.63 Mn |
| Mar 31, 2025 | 1.82 Mn |
| Mar 31, 2025 | 1.82 Mn |
| Dec 31, 2024 | 2.90 Mn |
| Dec 31, 2024 | 2.90 Mn |
| Sep 30, 2024 | -2.50 Mn |
| Sep 30, 2024 | -2.50 Mn |
| Jun 30, 2024 | 2.42 Mn |
| Jun 30, 2024 | 2.42 Mn |
| Mar 31, 2024 | -2.37 Mn |
| Mar 31, 2024 | -2.37 Mn |
| Dec 31, 2023 | -9,000.00 |
| Dec 31, 2023 | -9,000.00 |
| Sep 30, 2023 | 1.31 Mn |
| Sep 30, 2023 | 1.31 Mn |